CRDF vs. ATHA, DTIL, ALGS, ADAP, FRLN, ADPT, KYTX, LXEO, CABA, and ALEC
Should you be buying Cardiff Oncology stock or one of its competitors? The main competitors of Cardiff Oncology include Athira Pharma (ATHA), Precision BioSciences (DTIL), Aligos Therapeutics (ALGS), Adaptimmune Therapeutics (ADAP), Freeline Therapeutics (FRLN), Adaptive Biotechnologies (ADPT), Kyverna Therapeutics (KYTX), Lexeo Therapeutics (LXEO), Cabaletta Bio (CABA), and Alector (ALEC). These companies are all part of the "medical" sector.
Athira Pharma (NASDAQ:ATHA) and Cardiff Oncology (NASDAQ:CRDF) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, institutional ownership, risk, dividends, earnings, profitability, media sentiment, community ranking and analyst recommendations.
Cardiff Oncology received 20 more outperform votes than Athira Pharma when rated by MarketBeat users. Likewise, 62.30% of users gave Cardiff Oncology an outperform vote while only 58.06% of users gave Athira Pharma an outperform vote.
In the previous week, Athira Pharma had 1 more articles in the media than Cardiff Oncology. MarketBeat recorded 3 mentions for Athira Pharma and 2 mentions for Cardiff Oncology. Cardiff Oncology's average media sentiment score of 1.55 beat Athira Pharma's score of 0.94 indicating that Athira Pharma is being referred to more favorably in the media.
Cardiff Oncology has higher revenue and earnings than Athira Pharma. Cardiff Oncology is trading at a lower price-to-earnings ratio than Athira Pharma, indicating that it is currently the more affordable of the two stocks.
Athira Pharma currently has a consensus price target of $19.00, indicating a potential upside of 625.19%. Cardiff Oncology has a consensus price target of $10.50, indicating a potential upside of 230.19%. Given Cardiff Oncology's higher possible upside, equities research analysts clearly believe Athira Pharma is more favorable than Cardiff Oncology.
Athira Pharma has a net margin of 0.00% compared to Athira Pharma's net margin of -6,594.92%. Athira Pharma's return on equity of -54.54% beat Cardiff Oncology's return on equity.
57.1% of Athira Pharma shares are held by institutional investors. Comparatively, 16.3% of Cardiff Oncology shares are held by institutional investors. 19.8% of Athira Pharma shares are held by insiders. Comparatively, 7.8% of Cardiff Oncology shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Athira Pharma has a beta of 2.83, suggesting that its share price is 183% more volatile than the S&P 500. Comparatively, Cardiff Oncology has a beta of 2.02, suggesting that its share price is 102% more volatile than the S&P 500.
Summary
Athira Pharma and Cardiff Oncology tied by winning 8 of the 16 factors compared between the two stocks.
Get Cardiff Oncology News Delivered to You Automatically
Sign up to receive the latest news and ratings for CRDF and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CRDF and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cardiff Oncology Competitors List
Related Companies and Tools
